Enhanced immunity against SARS-CoV-2 in returning Chinese individuals

References

• Health Organization (WHO). WHO coronavirus (COVID-19) dashboard. [ accessed 2023 Apr 28] https://covid19.who.int/.
   Google Scholar
• Kang S, Yang M, Hong Z, Zhang L, Huang Z, Chen X, He S, Zhou Z, Zhou Z, Chen Q, et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B. 2020;10(7):1228–12. doi:10.1016/j.apsb.2020.04.009.
   PubMed Web of Science ®Google Scholar
• Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics after a national immunization program in Israel. Nat Med. 2021;27(6):1055–61. doi:10.1038/s41591-021-01337-2.
   PubMed Web of Science ®Google Scholar
• Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202–21. doi:10.1016/j.cmi.2021.10.005.
   PubMed Web of Science ®Google Scholar
• García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, Guijarro LG, García-Honduvilla N, Asúnsolo A, Bujan J, et al. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines (Basel). 2021;9(5):433. doi:10.3390/vaccines9050433.
   PubMed Web of Science ®Google Scholar
• Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, O’Toole Á, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593(7858):266–9. doi:10.1038/s41586-021-03470-x.
   PubMed Web of Science ®Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438–43. doi:10.1038/s41586-021-03402-9.
   PubMed Web of Science ®Google Scholar
• Ozer EA, Simons LM, Adewumi OM, Fowotade AA, Omoruyi EC, Adeniji JA, Lorenzo-Redondo R. High prevalence of SARS-CoV-2 B. 1.1. 7 (UK variant) and the novel B. 1.5. 2.5 lineage in Oyo State, Nigeria. Medrxiv. 2021;4(9):21255206.
   Google Scholar
• Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, Crispim MAE, Sales FCS, Hawryluk I, McCrone JT, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372(6544):815–21. doi:10.1126/science.abh2644.
   PubMed Web of Science ®Google Scholar
• Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing LLC.; 2023.
   Google Scholar
• Sarkar A, Omar S, Alshareef A, Fanous K, Sarker S, Alroobi H, Zamir F, Yousef M, Zakaria D. The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: a systematic review. Hum Vaccin Immunother. 2023;19(1):2212568. doi:10.1080/21645515.2023.2212568.
   PubMed Web of Science ®Google Scholar
• Tian S, Liu T, Zhao XJ, Liu X-L, Li X-L, Du K-G, Fang L-Q, Kou Z-Q, Wei Y-H, Wang G-L, et al. Neutralization against emerging Omicron subvariants after SARS-CoV-2 reinfection. J Infect. 2023;87(6):598–601. doi:10.1016/j.jinf.2023.09.013.
   PubMed Web of Science ®Google Scholar
• Laird-Gion J, Dionne A, Gauvreau K, Baker A, Day-Lewis M, de Ferranti S, Friedman K, Khan N, Mahanta S, Son MB, et al. MIS-C across three SARS-CoV-2 variants: changes in COVID-19 testing and clinical characteristics in a cohort of U.S. children. Eur J Pediatr. 2023;182(6):2865–72. doi:10.1007/s00431-023-04968-4.
   PubMed Web of Science ®Google Scholar
• Del Águila-Mejía J, Wallmann R, Calvo-Montes J, Rodríguez-Lozano J, Valle-Madrazo T, Aginagalde-Llorente A. Secondary attack rate, transmission and incubation periods, and serial interval of SARS-CoV-2 Omicron variant, Spain. Emerg Infect Dis. 2022;28(6):1224–8. doi:10.3201/eid2806.220158.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, Bruxvoort KJ, Tubert JE, Florea A, Ku JH, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28(5):1063–71. doi:10.1038/s41591-022-01753-y.
   PubMed Web of Science ®Google Scholar
• Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, Wellington E, Khawam J, Munro K, Cole M, et al. Protection against SARS-CoV-2 after covid-19 vaccination and previous infection. N Engl J Med. 2022;386(13):1207–20. doi:10.1056/NEJMoa2118691.
   PubMed Web of Science ®Google Scholar
• Wahid M, Jawed A, Mandal RK, Dailah HG, Janahi EM, Dhama K, Somvanshi P, Haque S. Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies. Eur Rev Med Pharmacol Sci. 2021;25(18):5857–64. doi:10.26355/eurrev_202109_26805.
   PubMed Web of Science ®Google Scholar
• Tareq AM, Emran TB, Dhama K, Dhawan M, Tallei TE. Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic. Hum Vaccin Immunother. 2021;17(11):4126–7. doi:10.1080/21645515.2021.1963601.
   PubMed Web of Science ®Google Scholar
• Link-Gelles R, Levy ME, Natarajan K, Reese SE, Naleway AL, Grannis SJ, Klein NP, DeSilva MB, Ong TC, Gaglani M, et al. Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during omicron BA.4 and BA.5 sublineage periods. JAMA Netw Open. 2023;6(3):e232598. doi:10.1001/jamanetworkopen.2023.2598.
   PubMed Web of Science ®Google Scholar
• Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C, Kreiss Y, Alroy-Preis S, Regev-Yochay G, Mendelson E, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N Engl J Med. 2022;386(5):492–4. doi:10.1056/NEJMc2119358.
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–100. doi:10.1016/S0140-6736(21)02249-2.
   PubMed Web of Science ®Google Scholar
• Edara VV, Manning KE, Ellis M, Lai L, Moore KM, Foster SL, Floyd K, Davis-Gardner ME, Mantus G, Nyhoff LE, et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. Cell Rep Med. 2022;3(2):100529. doi:10.1016/j.xcrm.2022.100529.
   PubMedGoogle Scholar
• Moscara L, Venerito V, Martinelli A, Di Lorenzo A, Toro F, Violante F, Tafuri S, Stefanizzi P. Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study. Vaccine. 2023;41(38):5655–61. doi:10.1016/j.vaccine.2023.07.043.
   PubMed Web of Science ®Google Scholar
• Franks J, Gruss B, Mulas-Granados C, Patnam M, Weber S. Reopening strategies, mobility and COVID-19 infections in Europe: panel data analysis. BMJ Open. 2022;12(2):e055938. doi:10.1136/bmjopen-2021-055938.
   PubMed Web of Science ®Google Scholar
• Quilty BJ, Clifford S, Hellewell J, Russell TW, Kucharski AJ, Flasche S, Edmunds WJ, Atkins KE, Foss AM, Waterlow NR, et al. Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling study. Lancet Public Health. 2021;6(3):e175–e183. doi:10.1016/S2468-2667(20)30308-X.
   PubMed Web of Science ®Google Scholar
• Wells CR, Townsend JP, Pandey A, Moghadas SM, Krieger G, Singer B, McDonald RH, Fitzpatrick MC, Galvani AP. Optimal COVID-19 quarantine and testing strategies. Nat Commun. 2021;12(1):356. doi:10.1038/s41467-020-20742-8.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Zhong NS. Strategies for reopening in the forthcoming COVID-19 era in China. Nat Sci Rev. 2022;9(3):nwac054. doi:10.1093/nsr/nwac054.
   PubMed Web of Science ®Google Scholar
• Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, Hou J, Huang X, Li D, Ma T, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020;26(8):1193–5. doi:10.1038/s41591-020-0949-6.
   PubMed Web of Science ®Google Scholar
• The Boston Globe. Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus. https://www.bostonglobe.com/2020/04/17/business/nearly-third-200-blood-samples-taken-chelsea-show-exposure-coronavirus/.
   Google Scholar
• Vimercati L, Stefanizzi P, De Maria L, Caputi A, Cavone D, Quarato M, Gesualdo L, Lopalco PL, Migliore G, Sponselli S, et al. Large-scale IgM and IgG SARS-CoV-2 serological screening among healthcare workers with a low infection prevalence based on nasopharyngeal swab tests in an Italian university hospital: perspectives for public health. Environ Res. 2021;195:110793. doi:10.1016/j.envres.2021.110793.
   PubMed Web of Science ®Google Scholar
• De Maria L, Sponselli S, Caputi A, Pipoli A, Giannelli G, Delvecchio G, Zagaria S, Cavone D, Stefanizzi P, Bianchi FP, et al. Comparison of three different waves in Healthcare Workers during the COVID-19 pandemic: a retrospective observational study in an Italian university hospital. J Clin Med. 2022;11(11):3074. doi:10.3390/jcm11113074.
   PubMed Web of Science ®Google Scholar
• Lu J, du Plessis L, Liu Z, Hill V, Kang M, Lin H, Sun J, François S, Kraemer MUG, Faria NR, et al. Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China. Cell. 2020;181(5):997–1003.e9. doi:10.1016/j.cell.2020.04.023.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Xu J, Ma B, Chen G, Wang Z, Wang S, Jing N, Zhang J, Wang B, Yan W, et al. Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: a prospective, multicenter, longitudinal study. Front Immunol. 2023;14:1107866. doi:10.3389/fimmu.2023.1107866.
   PubMed Web of Science ®Google Scholar
• Huang X, Liang C, Li M, Chen H, Li Z, Ruan Q, Hu X, Zeng L, Lin H, Zhao W, et al. Refocus on immunogenic characteristics of convalescent COVID-19 challenged by prototype SARS-CoV-2. Vaccines (Basel). 2023;11(1):123. doi:10.3390/vaccines11010123.
   PubMed Web of Science ®Google Scholar
• WHO. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.
   Google Scholar
• General Administration of Customs of the People’s Republic of China. http://www.customs.gov.cn//customs/302249/2480148/4761081/index.html.
   Google Scholar
• Yu P, Liu Z, Zhu Z, Yang J, Deng M, Chen M, Lai C, Kong W, Xiong S, Wan L, et al. Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees. Virol Sin. 2023;38(2):233–43. doi:10.1016/j.virs.2022.12.008.
   PubMed Web of Science ®Google Scholar
• Pape KA, Dileepan T, Kabage AJ, Kozysa D, Batres R, Evert C, Matson M, Lopez S, Krueger PD, Graiziger C, et al. High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines. Cell Rep. 2021;37(2):109823. doi:10.1016/j.celrep.2021.109823.
   PubMed Web of Science ®Google Scholar
• Sokal A, Barba-Spaeth G, Fernández I, Broketa M, Azzaoui I, de La Selle A, Vandenberghe A, Fourati S, Roeser A, Meola A, et al. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity. 2021;54(12):2893–907.e5. doi:10.1016/j.immuni.2021.09.011.
   PubMed Web of Science ®Google Scholar
• Dhakal S, Yu T, Yin A, Pisanic N, Demko ZO, Antar AAR, Cox AL, Heaney CD, Manabe YC, Klein SL, et al. Reconsideration of antinucleocapsid IgG antibody as a marker of SARS-CoV-2 infection postvaccination for mild COVID-19 patients. Open Forum Infect Dis. 2023;10(1):ofac677. doi:10.1093/ofid/ofac677.
   PubMed Web of Science ®Google Scholar
• Van Elslande J, Gruwier L, Godderis L, Vermeersch P. Estimated half-life of SARS-CoV-2 anti-spike antibodies more than double the half-life of anti-nucleocapsid antibodies in healthcare workers. Clin Infect Dis. 2021;73(12):2366–8. doi:10.1093/cid/ciab219.
   PubMed Web of Science ®Google Scholar
• Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, Milo R, Alroy-Preis S, Ash N, Huppert A, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24):e85. doi:10.1056/NEJMoa2114228.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O’Brien KL, Smith PG, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–44. doi:10.1016/S0140-6736(22)00152-0.
   PubMed Web of Science ®Google Scholar
• Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra RK, Chakraborty S, Zhou H, Islam MR, Mamada SS, Kusuma HI, et al. Global emerging Omicron variant of SARS-CoV-2: impacts, challenges and strategies. J Infect Public Health. 2023;16(1):4–14. doi:10.1016/j.jiph.2022.11.024.
   PubMed Web of Science ®Google Scholar
• Callaway E. Why does the Omicron sub-variant spread faster than the original? Nature. 2022;602(7898):556–7. doi:10.1038/d41586-022-00471-2.
   PubMedGoogle Scholar
• WHO. Statement on the update of WHO’s working definitions and tracking system for SARS-CoV-2 variants of concern and variants of interest. https://www.who.int/news/item/16-03-2023-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest.
   Google Scholar
• Chen X, Chen Z, Azman AS, Sun R, Lu W, Zheng N, Zhou J, Wu Q, Deng X, Zhao Z, et al. Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants induced by natural infection or vaccination: a systematic review and pooled analysis. Clin Infect Dis. 2022;74(4):734–42. doi:10.1093/cid/ciab646.
   PubMed Web of Science ®Google Scholar
• Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin K-M, Muñoz Sandoval D, Pieper FP, Butler DK, Liu S, Joy G, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Sci. 2022;377(6603):eabq1841. doi:10.1126/science.abq1841.
   PubMed Web of Science ®Google Scholar
• Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, Wan H, Schubert M, Cassaniti I, Wang Y, et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun. 2022;13(1):2670. doi:10.1038/s41467-022-30340-5.
   PubMed Web of Science ®Google Scholar
• Sapkota B, Saud B, Shrestha R, Al-Fahad D, Sah R, Shrestha S, Rodriguez-Morales AJ. Heterologous prime–boost strategies for COVID-19 vaccines. J Travel Med. 2021;29(3):taab191. doi:10.1093/jtm/taab191.
   Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, Takhar HS, Ogun OA, Simmons SR, Zamparo JM, et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study. Lancet Reg Health Am. 2022;9:100198. doi:10.1016/j.lana.2022.100198.
   PubMedGoogle Scholar
• Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andréll J, Braesch-Andersen S, Cassaniti I, Percivalle E, Sarasini A, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection. Med. 2021;2(3):281–95.e4. doi:10.1016/j.medj.2021.02.001.
   PubMedGoogle Scholar
• Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, Takehara KK, Eggenberger J, Hemann EA, Waterman HR, et al. Functional SARS-CoV-2-Specific immune memory persists after mild COVID-19. Cell. 2021;184(1):169–83.e17. doi:10.1016/j.cell.2020.11.029.
   PubMed Web of Science ®Google Scholar
• Vaisman-Mentesh A, Dror Y, Tur-Kaspa R, Markovitch D, Kournos T, Dicker D, Wine, Y. SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over time. MedRxiv. 2020. doi:10.1101/2020.08.23.20179796.
   Google Scholar
• Li L, Muftuoglu M, Liang S, Basyal M, Jiangxing LV, Akdogan ME, Chen K, Andreeff M, Flowers CR, Parmar S, et al. In-depth analysis of SARS-CoV-2–specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight. 2022;7(7):e156559. doi:10.1172/jci.insight.156559.
   PubMed Web of Science ®Google Scholar
• Liu B, Su X, Yu G, Yang S, Wang F, Huang T, Zhou L, Hui Z, Liao Y, Qiu Y, et al. An automated chemiluminescent immunoassay (CLIA) detects SARS-CoV-2 neutralizing antibody levels in COVID-19 patients and vaccinees. Int J Infect Dis. 2022;115:116–25. doi:10.1016/j.ijid.2021.12.316.
   PubMed Web of Science ®Google Scholar
• Laurén I, Havervall S, Ng H, Lord M, Pettke A, Greilert‐Norin N, Gabrielsson L, Chourlia A, Amoêdo‐Leite C, Josyula VS, et al. Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. Immunity Inflam Dis. 2022;10(4):e595.57. doi:10.1002/iid3.595.
   PubMed Web of Science ®Google Scholar
• Bonifacius A, Tischer-Zimmermann S, Dragon AC, Gussarow D, Vogel A, Krettek U, Gödecke N, Yilmaz M, Kraft ARM, Hoeper MM, et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 2021;54(2):340–54.e6. doi:10.1016/j.immuni.2021.01.008.
   PubMed Web of Science ®Google Scholar
• Karuna S, Li SS, Grant S, Walsh SR, Frank I, Casapia M, Trahey M, Hyrien O, Fisher L, Miner MD, et al. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: a cohort study. PLoS Med. 2021;18(12):e1003868. doi:10.1371/journal.pmed.1003868.
   PubMed Web of Science ®Google Scholar
• Li JX, Wu SP, Guo XL, Tang R, Huang B-Y, Chen X-Q, Chen Y, Hou L-H, Liu J-X, Zhong J, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022;10(8):739–48. doi:10.1016/S2213-2600(22)00087-X.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xing S, Liang D, Hu W, Ke C, He J, Yuan R, Huang Y, Li Y, Liu D, et al. Differential antibody response to inactivated COVID-19 vaccines in healthy subjects. Front Cell Infect Microbiol. 2021;11:791660. doi:10.3389/fcimb.2021.791660.
   PubMed Web of Science ®Google Scholar
• Huang YF, Hsu FC, Wu JJ, Lin YL, Liu MT, Yang CH, Chou YJ. Longitudinal neutralizing antibody responses after SARS-CoV-2 infection: a convalescent cohort study in Taiwan. J Microbiol Immunol Infect. 2023;S1684-1182(23):00072–5.
   Google Scholar
• Yamamoto S, Tanaka A, Ohmagari N, Yamaguchi K, Ishitsuka K, Morisaki N, Kojima M, Nishikimi A, Tokuda H, Inoue M, et al. Use of heated tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers. Prev Med. 2022;161:107123. doi:10.1016/j.ypmed.2022.107123.
   PubMed Web of Science ®Google Scholar
• Rao S, Baranova A, Cao H, Chen J, Zhang X, Zhang F. Genetic mechanisms of COVID-19 and its association with smoking and alcohol consumption. Brief Bioinform. 2021;22(6):bbab284. doi:10.1093/bib/bbab284.
   PubMed Web of Science ®Google Scholar
• Wall TL, Ehlers CL. Acute effects of alcohol on P300 in Asians with different ALDH2 genotypes. Alcohol Health Res World. 1995;19(3):617–22. doi:10.1111/j.1530-0277.1995.tb01557.x.
   Google Scholar
• Li Z, Liu S, Li F, Li Y, Li Y, Peng P, Li S, He L, Liu T. Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis. Front Immunol. 2022;13:965971. doi:10.3389/fimmu.2022.965971.
   PubMed Web of Science ®Google Scholar